Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

The article notes an upcoming oral presentation featuring updated data from the FIT-001 Phase 1a study evaluating darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients. No efficacy/safety figures, endpoints, or guidance changes are provided in the text, so near-term market impact is likely limited pending the actual trial results.

Analysis

The article notes an upcoming oral presentation featuring updated data from the FIT-001 Phase 1a study evaluating darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients. No efficacy/safety figures, endpoints, or guidance changes are provided in the text, so near-term market impact is likely limited pending the actual trial results.